Literature DB >> 22504915

New challenges in viral hepatitis.

David Thomas1, Fabien Zoulim.   

Abstract

Over the past few decades there has been remarkable progress in viral hepatitis. Beginning with discovery of the viral agents, we now have reliable methods to diagnose and monitor all hepatitis virus infections, as well significant advances in treatment and prevention. Nonetheless, important challenges remain. This supplement to Gut looks forward to the next generation of challenges in the field of viral hepatitis, and this introductory article highlights several key issues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504915     DOI: 10.1136/gutjnl-2012-302122

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.

Authors:  Bingqian Qu; Yi Ni; Florian A Lempp; Florian W R Vondran; Stephan Urban
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

2.  IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells.

Authors:  Shuye Zhang; Banishree Saha; Karen Kodys; Gyongyi Szabo
Journal:  J Hepatol       Date:  2013-05-07       Impact factor: 25.083

3.  Seroprevalence of Hepatitis A among Students Enrolled in Tehran University of Medical Sciences during 2011.

Authors:  Anahita Rabiee; Sina Nikayin; Seyed Reza Hashemi; Mostafa Mohaghegh; Marzieh Amini; Roozbeh Rabiee; Shahin Merat
Journal:  Middle East J Dig Dis       Date:  2013-07

4.  Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors.

Authors:  L W Meredith; K Hu; X Cheng; C R Howard; T F Baumert; P Balfe; K F van de Graaf; U Protzer; J A McKeating
Journal:  J Gen Virol       Date:  2015-10-16       Impact factor: 3.891

Review 5.  Ever closer to a prophylactic vaccine for HCV.

Authors:  Leo Swadling; Paul Klenerman; Eleanor Barnes
Journal:  Expert Opin Biol Ther       Date:  2013-05-07       Impact factor: 4.388

Review 6.  Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.

Authors:  Fabien Zoulim; T Jake Liang; Alexander L Gerbes; Alessio Aghemo; Sylvie Deuffic-Burban; Geoffrey Dusheiko; Michael W Fried; Stanislas Pol; Jürgen Kurt Rockstroh; Norah A Terrault; Stefan Wiktor
Journal:  Gut       Date:  2015-11       Impact factor: 23.059

7.  Identification of a novel antimicrobial peptide from human hepatitis B virus core protein arginine-rich domain (ARD).

Authors:  Heng-Li Chen; Pei-Yi Su; Ya-Shu Chang; Szu-Yao Wu; You-Di Liao; Hui-Ming Yu; Tsai-Ling Lauderdale; Kaichih Chang; Chiaho Shih
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

Review 8.  Hepatitis B virus receptors and molecular drug targets.

Authors:  Eloi R Verrier; Che C Colpitts; Camille Sureau; Thomas F Baumert
Journal:  Hepatol Int       Date:  2016-03-15       Impact factor: 9.029

Review 9.  Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment.

Authors:  Iara Fabricia Kretzer; Andrea do Livramento; Joel da Cunha; Sabrina Gonçalves; Iraci Tosin; Celso Spada; Aricio Treitinger
Journal:  ScientificWorldJournal       Date:  2014-06-10

10.  Interferon-α-Enhanced CD100/Plexin-B1/B2 Interactions Promote Natural Killer Cell Functions in Patients with Chronic Hepatitis C Virus Infection.

Authors:  Yu He; Yonghong Guo; Chao Fan; Yingfeng Lei; Yun Zhou; Mingjie Zhang; Chuantao Ye; Guangxi Ji; Li Ma; Jianqi Lian; Jonathan P Moorman; Zhi Q Yao; Jiuping Wang; Chunqiu Hao; Ying Zhang; Zhansheng Jia
Journal:  Front Immunol       Date:  2017-11-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.